Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Abbott to Separate into 2 Companies
October 21, 2011
-
BUSINESS Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
-
REGULATORY MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
-
COMMENTARY Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
BUSINESS Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
-
ORGANIZATION Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
-
REGULATORY PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
-
BUSINESS MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
-
REGULATORY Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
-
REGULATORY MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
-
REGULATORY Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
-
BUSINESS Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
-
BUSINESS Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
-
REGULATORY Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
-
ORGANIZATION 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
-
BUSINESS Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
-
ORGANIZATION Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
-
BUSINESS Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
-
BUSINESS Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
-
BUSINESS Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…